Illuminate PD1/PD-L1 interactions – new product out! 23-06-12 Uppsala Navinci expands its portfolio to unravel PD1 signaling, introducing the fluorescent assay, Naveni™ PD1/PD-L1 Atto 647N. With Naveni™ PD1/PD-L1 Atto 647N, you can now achieve a comprehensive visualization of the tumor microenvironment through co-staining. Illuminate PD1/PD-L1 interactions like never before and gain a deeper understanding of…
Navinci at EACR 2023 Congress – Unleashing Innovation 23-06-12 Uppsala A new product will be unveiled at the EACR Congress, where the Navinci team, consisting of Ida Hansson (Scientific Sales Specialist), Eva Auieong (Laboratory Manager), Hampus Elofsson (Senior Scientist), and Daniel Ekman (Customer Support Manager), will showcase our latest developments at booth 79. Make sure…
Navinci is a silver sponsor at Spatial Biology US 23-06-08 Uppsala Don’t miss the opportunity to meet our team consisting of Inge Cyrén (Area Manager North America), Subham Basu (CBO), and Doroteya Raykova (Applications Scientist). Doroteya Raykova will present our latest advancements in spatial proteomics (June 8th 12:40). She will explore the fascinating world of protein-protein interactions (PPIs) and shed light…
Spatial Biology UK – latest innovations in spatial research & technologies 23-04-21 Uppsala Navinci is joining Spatial Biology UK an Oxford Global event in London April 25-26th , a 2-day event that explores spatial research: from the application of spatial technologies in biology through to topical updates from spatial genomics, transcriptomics, metabolomics and spatial bioinformatics.…
Dr Subham Basu as new Chief Business Officer Press release Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the appointment of Dr Subham Basu as new Chief Business Officer, effective April 11th 2023. Dr Subham Basu will join Navinci to lead the organizational build-up and international commercialization…
Navinci at AACR – new research data and product developments 31-03-2023 Uppsala Navinci will attend AACR on April 14-19th in Orlando, US. We will showcase our latest product designs and tell you what is new in protein-protein interaction technology. You can find us in the exhibition hall (booth 1771) and at the scientific sessions with four poster presentations including…
Exhibition at SciLifeLab 23-03-29 Uppsala Are you in Uppsala? Stop by BMC, Navet, and the Life Science exhibition! We will be there on March 30th, between 09.00-15.00, this is a chance to receive information and updates from us and 9 others of the leading life science companies in Sweden (and to get some goodies). SciLifeLab…
Seminar: How to detect protein-protein interactions – Latest innovations in Proximity Ligation Technology March 15th, Biomedicum D1012 Karolinska Institutet, Solna Sweden We’re excited to invite you to our in-person seminar! In this session, you will learn how to visualize protein interplay in situ and how the latest Naveni proximity ligation technologies are pioneering molecular biology research. …
Navinci Diagnostics AB appoints Eva Pisa as chairman, further strengthens the leadership team, and establishes a Scientific Advisory Board In line with the company’s vision of becoming a leader in spatial proteomics, Navinci further strengthens its organization and is pleased to announce the appointment of Dr. Eva Pisa as new chairman of the board, Dr.…
An eye-opening solution for tissue samples – launch of NaveniFlex™ Tissue Looking for protein-protein interactions or post-translational modifications in tissues? We’ve got you covered. The advanced Naveni™ proximity ligation technology we developed for NaveniFlex™ Tissue kits are tailor-made to overcome common background challenges in tissue samples. The kits are optimized for tissue samples to deliver…
Discover the secret life of proteins – simultaneously visualize two proteins in a free and complex state Ever wish there were a way to take a snapshot of two proteins as they interact or remain unbound? Now, the door is open to study protein interplay and functional states while keeping the structural integrity of cells.…
Here to make a difference – the first PD1/PD-L1 interaction assay Immune checkpoint inhibitors have revolutionized cancer immunotherapy, and more than 3000 anti-PD1/PD-L1 therapies are currently in clinical trials. The leading technology used to determine whether a patient is likely to benefit from PD1/PD-L1 immunotherapy is PD-L1 immunohistochemistry. However, this test doesn’t reveal whether the…